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Tardive dyskinesia (TD) can be a disabling condition and is frequently refractory to medical therapy. Over
the past decade there have been many reports of TD patients experiencing signiﬁcant beneﬁt with deep
brain stimulation (DBS) of the globus pallidus interna (GPi). The growing literature on this treatment
option for TD consists predominantly of case reports and series. The reported beneﬁt ranges widely, but
the majority of cases experienced at least a 50% improvement in symptoms. The anatomical distribution
of dyskinesias has not clearly inﬂuenced outcome, though ﬁxed postures appear less likely to improve
than phasic movements. Onset of beneﬁt can be immediate or take months, and beneﬁt is sustained in
most cases, for at least 6 months and up to several years. A wide variety of voltages, frequencies, and
pulse widths have demonstrated efﬁcacy. A small number of reports which examined psychiatric
symptoms before and after surgery did not ﬁnd any decline, and in some cases revealed improvement in
mood. However, these overall positive results should be interpreted with caution, as the majority of
reports lacked blinded assessments, control groups, or standardized therapy parameters. Finally,
we present an illustrative case of refractory tardive dyskinesia treated with GPi-DBS with 5 years of
follow-up and 4 accompanying video segments.
Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Tardive dyskinesia (TD) is a disabling persistent condition that
results from use of dopamine receptor blocking agents. Medical
management, consisting of benzodiazepines, anticholinergics,
muscle relaxants, dopamine depleting agents, and botulinum toxinch, Education, and Clinical Center
ax: þ1 215 823 5815.
 CC BY-NC-ND license.injections, is often insufﬁcient and fraught with side effects. In the
last decade there have been several reported cases of deep brain
stimulation (DBS) used to treat TD [1e6], and in particular tardive
dystonia [7e23], usually targeting the globus pallidus interna (GPi),
which has also been the target used to treat other hyperkinetic
movement disorders [24,25]. Cases of successful thalamic or(PADRECC), Philadelphia Veterans Affairs Medical Center, 3900 Woodland Avenue,
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review will focus on pallidal stimulation only, as this was used in
the vast majority of published cases. With the exception of 3 cases
of tardive dystonia which did not respond to GPi-DBS [15,20], the
response in these reports has generally been positive, but has also
been highly variable with regard to the timing, degree, and dura-
tion of improvement. Reasons for this variability are unclear, but
are likely related to the heterogeneity of tardive phenomenology,
inconsistencies in lead location within the GPi, a wide range of DBS
parameters utilized, and differing outcome measures at varying
lengths of follow-up.2. Review of the literature
2.1. Phenomenology
More cases of GPi-DBS treatment of tardive dystonia have been
reported (52 cases in 16 articles) than of tardive dyskinesias (14
cases in 5 articles), presumably owing to the success seenwith DBS
in primary dystonias. Nineteen of the tardive dystonia cases are
reported in 9 articles that present series of various types of dys-
tonia, and in these articles criteria for the diagnosis of TD were not
presented. In the majority of reports of pure tardive dystonia, the
criteria proposed by Adityanjee et al. [26] in 1999 are used for
diagnosis, while the remainder use the criteria put forth by Burke
et al. in 1982 [27]. Key features of both criteria include the presence
of chronic dystonia, a history of anti-psychotic drug use preceding
or concurrent with the onset of dystonia, the absence of family
history of dystonia, and exclusion of other causes of secondary
dystonia [27]. The difference between the two criteria is in the
purity of the dystonia symptoms: whereas the Burke criteria stip-
ulate that dystonia must be the primary symptom, Adityanjee et al.
propose 4 subtypes depending on the degree of dystonia relative to
other movements [26]. Tardive dystonia, using these criteria, is
thought to be less common, have a faster onset, and bemore painful
and distressing than tardive dyskinesias [26].
Despite these distinguishing characteristics, there is consider-
able overlap of tardive dystonia and dyskinesias, and the distinction
is not always clear, especially when there are phasic dystonic
movements. The above criteria for tardive dystonia allow for
concomitant choreiform dyskinesias; thus some reports of tardive
dystonia involve patients who have a mixed movement disorder.
Similarly, as the term dyskinesia is often taken to include both
dystonia and chorea, most reports of tardive dyskinesias also
involve patients with both phenomena. The close examination and
classiﬁcation of phenomenology in tardive syndromes is important
as it may inﬂuence how patients will respond to GPi-DBS, including
timing of onset, degree, and duration of improvement.2.2. Outcomes
Reported responses of tardive dyskinesia or dystonia to pallidal
stimulation are summarized in Table 1. In the 12 patients for whom
a Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) total score
is reported, themean improvement is 62%. Of these 12 patients, 67%
had >50% improvement, and 50% experienced >75% improvement.
In the 42 patients with BFMDRS motor and disability subscores
reported, the mean improvements are 71% for the motor score and
65% for the disability score. Motor subscores improved by >50% in
79% of patients, and by>75% in 64% of patients. Disability subscores
decreased by >50% in 71% of patients and by >75% in 48% of
patients. In the 28 patients for whom an AIMS score is reported, the
mean improvement is 69%; 82% of these improved by at least 50%,
and 43% improved by >75%. However, it is important to note thatnone of these reports employed a sham control group and many of
the assessments were unblinded.
Several case series have indicated that the response of chorea and
dystonia to GPi-DBS is of equal degree. In 2007, Damier et al. pub-
lished the only prospective trialwith blinded assessment of GPi-DBS
for tardive dyskinesias [6]. Symptoms were measured using the
Extrapyramidal Symptoms Rating Scale (ESRS) and the Abnormal
Involuntary Movement Scale (AIMS). The 10 patients enrolled, as
a group, had both dystonic and choreiform movements, which
responded equally in degree to the DBS, as measured using the
dystonia and chorea subscores of the ESRS. Themean total ESRS and
AIMS scores at 6 months had declined by 61% (range 44%e75%) and
56% (range 33e69%), respectively. A double-blind evaluation using
video recordings at 6 months was also performed, corroborating an
improvement,with ameandecrease in ESRS score of 50% (range 30e
66%). Similarly, Chang and colleagues reported 4 patients with
segmental or generalized dystonia as well as chorea, with a 71%
improvement in the Burke-Fahn-Marsden Dystonia Rating Scale
(BFMDRS) motor subscore and a 77% decline in the ESRS dyskinesia
subscore, suggesting comparable improvement of both phenomena
[11]. Trottenberg et al. reported a case series of 5 patients with
improvement of both axial phasic dystonic movements and oro-
buccolingual dyskinesias by 87% using the BFMDRS motor subscore
and78%using theAIMS, thoughdegree of responseof each symptom
is not reported separately [7]. Individual case reports noted differ-
ential response of axial and appendicular dyskinesias to stimulation,
but a speciﬁc pattern was not consistently reported [2,4,5].
In reports of tardive dystonia without mention of choreiform
movements, phasic dystonic movements appear to be more respon-
sive to GPi-DBS thanﬁxed abnormal postures [8,13,23]. In a large case
series of 9 patients, Gruber et al. found the degree of motor response
to be equal for orobuccolingual, axial, and limb dystonia, with 83%,
68%, and 79% improvements of BFMDRSmotor score, disability score,
and AIMS score, respectively, at last follow-up [12]. Similarly, Egidi
et al. reported 69 patients with dystonia, 32 of whom had secondary
dystonia including 5 with tardive dystonia, and found that the
anatomical distribution of dystonic symptoms in these patients did
not inﬂuencebeneﬁt [18]. However, Franzini et al. reported 2patients,
with 42% and 78% reductions in the BFMDRS, in whom orobuccolin-
gual dystonia was less responsive than cervical dystonia [8].
2.3. Onset and duration of beneﬁt
The onset of improvement of choreiform dyskinesias and dys-
tonia varies among reports. Two cases of tardive choreiform dyski-
nesias improved immediately [3,5], including one which improved
within 30e60 s of stimulation [5]. The 10 patients involved in
Damier’s prospective trial had improvement of their choreiform
symptoms within days [6], while other cases of chorea improved
more gradually, over 3 months [4] or 6 months [2,11]. While many
patients with tardive dystonia had gradual improvement over
weeks to months [6,9,11], similar to the response seen in primary
dystonias, several patients also had unexpected early improvement,
within a few days [7e10,12]. Notably, Capelle et al. report
improvement of phasic movements within days, and subsequent
improvement in tonic postures over weeks to months [10].
In all cases, beneﬁt was sustained at last follow-up. The duration
of study was limited to 6 months in Damier’s prospective trial of 10
patients. Follow-up of other cases has ranged from 5 months to 80
months (6.7 years). Twenty-two of these have been followed for up
to 1.5 years, 21 patients have been followed for more than 2 years,
and 2 have been followed for more than 5 years. In most cases no
signiﬁcant change in symptoms was seen during the follow-up
period. In a few reports with longer follow-up, the mean
improvement continued to increase from early follow-up to last
Table 1
Cases in the literature of pallidal stimulation for tardive dystonia or dyskinesias.
Author N Mode Contacts Amplitude (V)
Mean  SD (Range)
Frequency (Hz)
Mean  SD (Range)
Pulse width (ms)
Mean  SD (Range)
Scale Mean %
improvement
Yianni, 2003a 1 B Deepest contact without
AEs (), most superﬁcial
contact without AEs (þ)
4.0e7.0 (NS) 130e180 (NS) 150e240 (NS) BFMDRS (m/d/t)
AIMS
28/39/31
42
Eltahawy, 2004 1 M R Cþ2
L Cþ23
2.6 40 210 BFMDRS (t) 60
Schrader, 2004 1 NR NR 5.5 60 60 AIMS 63
Krause, 2004a 3 M Just above contact
producing phosphenes
Just below AEs, then
tapered to lowest
effective setting
130e180 (NS) 210 (NS) BFMDRS (m/d) 3/0
e2/0
1 lost to
follow-up
Franzini, 2005 2 M Cþ0 1.0 130 90 BFMDRS (t) 42 and 78
Halbig, 2005a 2 M NR R: 3.1  1.2 (1.5e5.0)
L: 3.1  1.1 (1.5e5.0) (NS)
142  32
(130e250) (NS)
106  55
(60e210) (NS)
BFMDRS (t) 77
93
Trottenberg, 2005 5 M NR 2.7  0.8 144  22 111  57 BFMDRS (m/d)
AIMS
87/96
78
Starr, 2006a 4 M 2Cþ (initial; NS) 2.5e3.6 (NS) 185 (NS) 210 (NS) BFMDRS (t) 100, 80, 53,
and 6
Cohen, 2007 1 M Cþ1 4.0 130 90 BFMDRS (m/d) 86/100
1 M Cþ1 3.4 130 120 BFMDRS (m/d) 64/53
Damier, 2007 10 M Inferior-most
without AEs
3.5  0.2 130 150 ESRS
AIMS
61
56
Egidi, 2007a 5 NR NR NR 100e185 60e450 BFMDRS (m/d) 47/55
Kosel, 2007 1 M R Cþ4
L Cþ1
R 3.8
L 3.5
130 90 BFMDRS (t) 35
Magarinos-Ascone
2008a
1 NS NS 2.5  0.2 (NS) 130e160 (NS) 118  5 (NS) BFMDRS (m/d) 48/44
Pretto, 2008a 1 NS NS 4.1 185 90 AIMS 90
Sako, 2008 6 M 1 or 2 most ventral 2.2  0.9 (1.3e3.8) 119  28 (60e135) 450 BFMDRS (m/d) 86/80
Gruber, 2009 9 Both Cþ1, 0þ1, or 1þ2 R 3.0  1.0
L 2.8  0.6
154  25 83  13 BFMDRS (m/d)
AIMS
83/68
79
Katsakiori,
2009a
1 M NR 2.5e4.5 (NS) 185 (NS) 210e450 (NS) BFMDRS (m/d) 41/30
Kefalopoulou,
2009
1 M Cþ01 2.5e3.6 185 250e450 BFMDRS (t)
AIMS
91
77
Capelle, 2010 3 B 12þ 4.5 (3.0e6.5) 130 210 BFMDRS (m/d) 84/72
1 M NR 160 90
Chang, 2010 5 M NR 3.0 (2.5e3.6) 93 (60e185) 201 (180e210) BFMDRS (m/d)
ESRS dyskinesia
71/48
77 (N ¼ 4)
Kim, 2011a 1 M NR 2.98 (NS) 88.75 (NS) 165 (NS) BFMDRS (m/d) 97/100
Abbreviations: AEs e adverse effects, M emonopolar, B e bipolar, R e right, L e left, C e case, NS e results reported are from dystonia group as a whole and not speciﬁc to TD
patients, NR e not reported, BFMDRS e Burke-Fahn-Marsden Dystonia Rating Scale, (t) e total, (m) emotor subscore, (d) e disability subscore, AIMS e Abnormal Involuntary
Movements Scale, ESRS e Extrapyramidal Symptoms Rating Scale.
a Reports of tardive dystonia patients within a larger cohort of primary and/or secondary dystonia patients.
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months and 18 months, the patients appeared to develop a toler-
ance to treatment, requiring escalation of stimulation [4,5]. These
same patients also developed rebound dyskinesias when the
stimulator was turned off, i.e., their dyskinesias were worse than
they had been prior to surgery [4,5].
2.4. Operative technique and complications
In all cases reviewed, the ventral GPi was targeted for electrode
implantation; in some reports, more speciﬁcally the posteroventral,
posteroventral lateral, or posteroventral medial GPi was targeted.
Nearly all reports described use of preoperative stereotactic MRI or
an MRI fused with stereotactic CT to deﬁne the anatomic target.
Target locations were similar in all cases, and ranged from 20 to
22mmlateral tomidline, 2 to 3mmanterior to the intercommissural
midpoint, and4 to6mmbelowthebicommissural line. Inone case, it
was decided to target the most ventral GPi, in order to selectively
stimulate the facial area, resulting in a target thatwas approximately
1e2mm above,1.5 mm rostral, and 2mmmedial to the usual target
in Parkinson’s disease and dystonia [2]. The number of tracks used
was inconsistently reported and was variable. Microelectrode
recording (MER) with linking of passive movements to assess GPi
neuronal activity was described in several reports [3e5,7,9e13,15e17,20,23]. Intraoperative macrostimulation was also used in many
cases to assess beneﬁt as well as to determine visual phosphene and
capsular stimulation thresholds [3,6,7,9e13,15,17,21,23]. Electrode
placement was anatomically conﬁrmed with post-operative MRI in
the majority of cases (40 patients in 10 reports), but several reports
did not mention post-operative imaging or noted only post-
operative skull X-rays. Although the latter cases used other means
for verifying placement in the target, such as MER or intraoperative
macrostimulation, the lack of anatomical conﬁrmation of ventral GPi
placement raises the possibility that variation in precise lead loca-
tion may have contributed to variation in outcomes.
Surgical complications were minimal. Of the 10 patients re-
ported by Damier et al., 1 patient required re-implantation of a lead
which was too lateral and anterior and provided no beneﬁt, and
another patient required ﬁxation of the stimulator to the clavicle
due to painful traction of the cable connection [6]. Of the 5 patients
reported by Chang et al., 1 patient suffered a venous infarct in the
pre-motor and supplementary motor areas, and another patient’s
battery replacement 10months after implantationwas complicated
by a chest site infection requiring temporary removal of the stim-
ulator and a 2-week course of antibiotics [11]. One patient reported
by Krause et al. returned to her home country shortly after surgery;
2 weeks later she underwent lead removal there for infection, and
was thereafter lost to follow-up [20]. One of the 4 patients reported
M.A. Spindler et al. / Parkinsonism and Related Disorders 19 (2013) 141e147144by Starr et al. suffered a multifocal left frontal hemorrhage 2 days
post-operatively, causing aphasia and hemiparesis, with MRI
revealing a venous infarction [15]. This patient recovered fully by in
3 months, but his dystonia did not respond to stimulation. The
complication rate of the 66 cases described in 21 reports is thus 9%
(6/66), which is similar to the complication rates reported in other
studies of GPi-DBS [28].
2.5. Stimulation parameters
DBS parameters were highly variable among the reports
(Table 1). The majority of stimulators were set in monopolar mode,
either with one or two cathodes. Exceptions included 3 patients
reported by Capelle et al., who were stimulated in bipolar mode
using contact 1 as cathode and contact 2 as anode, and 1 patient
reported by Yianni et al., stimulated in bipolar mode using the
deepest contact without adverse effects as the cathode and the
most superﬁcial contact without adverse effects as the anode
[10,19]. In 7 of the 9 patients reported by Gruber et al., mode was
individualized based on beneﬁcial and adverse effects, and was not
speciﬁed further [12]. In some reports, the process employed for
choosing active contacts was not described explicitly [3,4,7]. In
a few reports, the most ventral contacts without side effects were
stimulated [6,8,13], while in others, the choice of cathodewas based
on known anatomic position using intraoperative monitoring or
MRI [5], clinical beneﬁt and adverse effects [2,9,11], or a combina-
tion of the two [12]. Stimulation amplitude ranged from 1.0 V to
6.5 V, pulse width from 60 ms to 450 ms, and frequency from 40 Hz
to 185 Hz. In all but one report which maintained a stimulation
amplitude of 1.0 V [8], the voltage was titrated to optimal beneﬁt.
Likewise, in many reports the pulse width was adjusted during the
follow-up period to optimize response [3], or in case series was
reported as a range, implying adjustment [7,12]; though others do
not explicitly mention adjustments of pulse width [2,4,9]. Several
studies used a stable initial pulse width, and the choices varied
widely, including 60 ms, [5], 90 ms, [8], 150 ms in the Damier trial [6],
210 ms, [10,11], and 450 ms [13]. A number of individual case reports
or small series used a stable frequency of 130 Hz [2,8e10], with one
using a stable frequency of 185 [3]. The trial of 10 patients by
Damier et al. used a stable frequency of 130 Hz. The other series of
multiple patients usually employed a variety of frequencies tailored
to optimal patient response, reporting means of 144  22 [7],
154  25 [12], and 119  28 Hz [13], or a range of 145e185 Hz [11].
Of note, the patient reported by Eltahawy et al. demonstrated the
best clinical response to a low frequency of 40 Hz [4]. The marked
variability in settings used may indicate that lead locations were
dissimilar among cases, despite similar lead targets. Correlation of
stimulation parameters and outcomes with precise lead locations
requires further study.
2.6. Non-motor effects
Several patients experienced changes in their mood after surgery.
Of the 10 patients in Damier’s prospective trial in which mood was
measured and monitored using the Montgomery Asberg Depression
Rating Scale (MADRS),1 patient’smood signiﬁcantly improved, and 3
patients experienced a signiﬁcant worsening of mood, without
meeting criteria for a diagnosis of major depressive disorder [6]. The
depression improved over the ensuing 6 months, in 2 cases sponta-
neously, and in one case with antidepressant therapy. In 9 patients
reportedbyGruber et al., themeanMADRS score improvedbyamean
of 59% [12]. Kosel et al. reported a case with a 50% reduction in the
Hamilton Rating Scale for Depression (HRSD) score and a 27%
reduction in the Beck Depression Inventory (BDI) score [2]. One
patient each in Trottenberg’s and Sako’s case series had signiﬁcantimprovements in mood without objective measurements reported
[7,13]. Although suicidehasbeenobservedafterGPi-DBS in2dystonia
cases, this has not been reported in any tardive dystonia patients [29].
A few reports havemeasured changes in cognition after GPi-DBS
for tardive dyskinesia or dystonia. The Mini-Mental State Exam
(MMSE), Mattis Dementia Rating Scale (MDRS), Frontal Assessment
Battery (FAB), and Frontal Behavior Scale were all measured in 10
patients by Damier et al. before and after surgery, and revealed no
signiﬁcant change [6]. Gruber et al. used the MDRS, Multiple
Wording Test part B (MWT-B), Rey Auditory Verbal Learning Test,
and digit span tomeasure cognition in 9 patients, and also found no
signiﬁcant changes, although there was a trend towards improve-
ment in verbal ﬂuency post-operatively [12]. No cognitive deteri-
oration was described in any report, in contrast to published data
regarding slight decrements in cognitive performance following
GPi-DBS for PD [28].
Quality of life was measured by Gruber et al. in 9 patients using
the Medical Outcomes Study 36-item Short Form General Health
Survey, and the physical health subscore of this survey improved
signiﬁcantly by 46.1%. All other domains of quality of life in the
survey showed a trend towards improvement [12].
2.7. Pathophysiology and therapeutic mechanism
The mechanism by which GPi-DBS exerts its therapeutic effects
remainsunknown. Thisuncertainty is partially due to the lackof clear
understanding of the pathophysiology of tardive syndromes. The
earliest and most widely purported hypothesis alleges that chronic
dopamine receptor blockade with neuroleptic agents leads to
hypersensitivity of nigrostriatal postsynaptic dopamine receptors
[9,30,31]. With typical antipsychotics, which block primarily D2
receptors, this hypersensitivity may develop especially in D1 recep-
tors as they are repeatedly stimulated byendogenous dopamine. The
D1-mediated striatal output is primarily directed at the GPi and
substantia nigra pars reticulata; thus, hypersensitivity of D1 recep-
tors may lead to overactivity of the GPi [9,31]. Other hypotheses
implicate a deﬁciency of striatal GABA along with its synthesizing
enzyme, glutamic acid decarboxylase [32], and damage to striatal
cholinergic and GABAergic interneurons, possibly due to excitotox-
icityandoxidative stress due to free radicals producedwith increased
dopamine turnover [30,33]. Speciﬁcally, GABAergic interneurons
regulate the balance of direct and indirect pathways via feedforward
inhibition, and selective lesioning of these has been shown to
generate dyskinesias [30]. Teo et al. recently hypothesized that both
dopamine receptor hypersensitization and subsequent impaired
synaptic plasticity of striatal interneurons could cause an imbalance
of direct and indirect pathways, and ultimately an inability to reverse
the TD after withdrawal of the offending medication [30].
It remains unclear whether DBS exerts its effects via inhibition
or activation of the target nucleus, or a complex pattern of the two.
Initial studies of DBS mechanisms supported inhibition of activity
of the target, but DBS of the GPi and STN has been shown to directly
increase GPi output [34], and studies of downstream nuclei have
shown results consistent with activation of target nuclei [35,36].
DBS may suppress or interrupt abnormal ﬁring patterns in the
target nucleus, possibly via inducingmore regular activity, and thus
normalize output to the thalamocortical circuit, restoring motor
control [37]. Reduced and irregular ﬁring rates of the GPi have been
described in hyperkinetic states such as Huntington’s disease,
dystonia, and dopaminergic therapy-induced dyskinesias in animal
models and patients [38e40]; DBS of the GPi may increase the
frequency and induce more regular ﬁring patters in these condi-
tions [41]. Evidence for motor cortical effects of GPi-DBS has been
shown using PET and SPECT imaging to examine markers of brain
activity both on and off stimulation, which have demonstrated
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cortex, supplementary motor cortex, and prefrontal cortex with
stimulation [3,42]. More extensive discussion of potential DBS
mechanisms can be found elsewhere [37,43,44].
3. Illustrative case
The patient is a right-handed male veteran who ﬁrst developed
major depressionwith psychotic features at the age of 30, requiring
hospitalization, upon returning from the Persian Gulf War in 1994.
Thiothixene, a high-potency typical anti-psychotic with strong D2-
receptor afﬁnity, was started and continued for 9 years at doses of
6e12 mg daily with good control of psychosis. Other medications
included serotonin reuptake inhibitors and bupropion.
The patient ﬁrst noted bruxism, mouth movements, and
abnormal breathing in 2003, at the age of 38. Thiothixene was
changed to risperidone and benztropine was started. Over the
following year he developed involuntary blinking, gasping, and
chorea of the trunk and right hand. Resultant difﬁculty speaking,
chewing, swallowing, and breathing led to several emergency room
visits, where intramuscular benztropine provided temporary relief.
In early 2004, risperidone was tapered off, without any change in
TD or emergence of psychiatric symptoms. The patient declined
clozapine for fear of side effects.
On presentation to our clinic, he reported frequent biting of his
tongue, lips, and cheek, and difﬁculty maintaining sleep. Due to
dysphagia he required amechanical soft dietwith thickened liquids.
Medications included sertraline, trazodone, amantadine (200 mg/
day), benztropine (6 mg/day plus periodic injections), diphenhy-
dramine (200e250 mg/day as needed), and baclofen (20e30 mg/
day as needed). His regimen caused sedation, impaired concentra-
tion, blurred vision, drymouth, constipation, and urinary hesitation.
On examination he had oromandibular dystonia, blepharospasm,
grunting, gasping, head thrusting, andmild chorea of the right hand
(see video, segment 1).
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.parkreldis.2012.09.016.
Over the ensuing months, all anti-dyskinetic medications were
tapered, and low-dose reserpine was started, resulting in signiﬁ-
cant improvement. This beneﬁt waned a year later, prompting an
unsuccessful trial of botulinum toxin injections of the frontalis,
orbicularis oculi, levator anguli oris, orbicularis oris, and platysma
muscles. The addition of tetrabenazine at 25 mg/day (dose limitedFig. 1. Post-operative coronal (A) and axial (B) T2-weighted MRI imagesby cost) provided minor beneﬁt, and clonazepam was added, as
anxiety exacerbated his movements. One year later he had devel-
oped oral injuries which required frequent dental visits, retrocollis
with neck pain requiring cyclobenzaprine and opiates, abdominal
dystonia, and involuntary leg movements causing falls. In May
2006, his Abnormal Involuntary Movement Scale (AIMS) score was
36/42 and his Extrapyramidal Symptom Rating Scale (ESRS) score
was 76/187 (video, segment 2).
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.parkreldis.2012.09.016.
The patient underwent implantation of bilateral GPi-DBS in
August 2006, about 3.5 years into his disease course. Placement of
the leads was guided by stereotactic MRI-derived targets, namely,
21 mm lateral, 5 mm inferior, and 2 mm anterior to the mid-
commissural point, and microelectrode recordings (MER). Post-
operative MRI revealed suboptimal position of the right lead,
necessitating replacement the following day, again under stereo-
tactic MRI guidance, with intraoperative ﬂuoroscopic and post-
operative MRI conﬁrmation of placement (Fig. 1).
The stimulator was programmed immediately post-operatively,
utilizing the second most ventral contact in monopolar mode at an
amplitude of 1.5 V, pulse width of 90 ms, and frequency of 185 Hz
bilaterally. His stimulator voltage was titrated bilaterally to 3.2 V
over the next several months, during which time he reported
substantial reduction in his TD, especially his facial and appen-
dicular movements. Six months after surgery, his AIMS score was
14/42, a 67% improvement (video, segment 3), and several months
later it had improved by 71%. He experienced marked beneﬁt in all
subscores (facial, limb, overall severity) except for the truncal
movements, which have remained moderate since surgery. He was
continued on tetrabenazine, clonazepam, cyclobenzaprine, and
sertraline. Over the following 3 years, he suffered periodic wors-
ening of his TD, which improved with small adjustments to his
stimulator voltage or medications. The maximum voltage reached
was 3.6 V bilaterally, which was ultimately decreased back to 3.3 V
due to speech impairment. Changes in contact conﬁguration and
pulse width have conferred no objective improvement. In
December 2011, more than 5 years since surgery, his exam
demonstrated sustained improvement relative to his preoperative
condition, with an AIMS score of 16/42 (62% improvement) (video,
segment 4).
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.parkreldis.2012.09.016.demonstrating placement of leads in the ventral posterolateral GPi.
M.A. Spindler et al. / Parkinsonism and Related Disorders 19 (2013) 141e1471464. Conclusion
The existing literature suggests that pallidal DBS is effective for
both tardive dyskinesias and dystonia, and can provide sustained
alleviation of facial, axial, or limb symptoms. Although patients
they may experience early symptomatic relief, maximal beneﬁt
may take as many as 6 months to achieve. These reports suggest
that in patients who fail to receive adequate beneﬁt with GPi-DBS,
low frequencies and a wide variety of pulse widths should be
tested. Additionally, thus far, patients do not appear to experience
deterioration in their psychiatric illness after the surgery, and in
fact may enjoy an improvement in their mood. However, only
one of these reports was a prospective trial with blinded assess-
ment, and to date, there are no randomized, sham-controlled trials.
Trials of GPi-DBS in patients with TD using randomization, sham
control groups, blinded assessment, and longer-term follow-up are
needed to deﬁnitively address the variables discussed in this
review, and to allow consistent and efﬁcacious use of DBS in
treating TD syndromes.Author contributions
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